Relevium Launches Bioganix® on Walmart.com
Momentum Public Relations
Press Release: May 3 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that it has received approval to sell its biggest mover Bioganix® products on Walmart.com.
Highlights
- New and diverse revenue channel with over 400M monthly visitors
- Onboarding and approval to Walmart.com is complete
- Sales testing of Bioganix® products is currently online
- Bioganix® will launch best selling SKUs and customize a new offering for a new demographic
- Opens a new sales vertical and mitigates channel risk
Walmart.com will provide Relevium with access to 400M new visitors per month with a diverse customer demographic and profile. According to CBS MoneyWatch, Walmart.com shoppers are primarily young women and nearly half have families with kids and a diverse ethnic profile. Amazon and Walmart demographics are complementary thereby mitigating channel risk for the Bioganix® brand.
Aurelio Useche, CEO of Relevium stated: “The addition of the Walmart.com platform to the existing Amazon.com sales channel gives Bioganix® a new and diverse audience and should prove to be accretive to revenues going forward.” Mr. Useche continued: “Diversifying our sales channels also de-risks the reliance on individual marketplaces and allows us to reach new customers across the USA, Europe and Asia. This is a major step for the Company and our expectations are high.”
Abis Hussain, SMO of Relevium, stated: “The Operations Team has concluded that the audience and the competition on Walmart.com is very different than those in Amazon.com and should reflect nicely on the bottom line for the Company. As an added bonus, Walmart.com will be key to the introduction of full spectrum hemp oil products, which will prove to be extremely valuable going forward as we prepare to launch products related to the space.”
Bioganix® products have been available on the Walmart.com platform, on a test-basis, for sale and delivery in the United States of America as of May 1, 2018. Initially, the Company will be offering five (5) to eight (8) of its best-selling products on the platform and then evaluate which products will subsequently be made available.
Relevium has the intention of selling products from its current catalogue as well as new products that will be launched in 2018. New products will be centered around major themes in the health and wellness markets including weight management, sports performance, ketogenic diets and general well being offered through hemp-derived products.
Bioganix® products will now be widely available in the USA through Bioganix.com, Amazon.com and Walmart.com and imminently in the United Kingdom through Amazon.co.uk.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Creates Biocannabix Subsidiary and Targets Legal Cannabis Business
Momentum Public Relations
Press Release: April 19 2018
Relevium TechnologiesInc. (TSX VENTURE:RLV) (OTCQB:RLLVF) (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of Biocannabix Health Corporation (the “Subsidiary” or “BHC”), a Canadian wholly owned subsidiary structured to lead the development of the legal cannabis derivatives business for RLV. The Company projects to complete its ACMPR application for the Canadian marketplace within the current fiscal quarter and has begun to assemble its legal and regulatory team of experts within targeted jurisdictions.
Highlights
- Biocannabix Health Corporation to lead the Company’s legal cannabis initiatives
- Focus on developing a portfolio of high end consumer brands for North America
- Prepare for a global online marketplace for jurisdictions with a legal context
- Subsidiary anticipates applying for the necessary ACMPR licenses from Health Canada
- Initial commercial focus will be on industrial hemp derivatives such as CBG and CBD
As a Canadian company, Relevium will initially target the legal cannabinoids markets in North-America and develop medical, lifestyle and luxury consumer products aimed at supporting overall health and wellness. The Company’s newly created subsidiary is expected to begin the process of obtaining access to cannabis for medical purposes through the filing of an application for the appropriate licences from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The primary purpose of the application will be to enable the Company, through Biocannabix, to secure the appropriate legal authorizations to be able to distribute and sell medical cannabis products in Canada and service other jurisdictions in the export market.
Aurelio Useche, CEO of Relevium stated: “Our core business is health and wellness and the legal Cannabis derivative business is growing exponentially in our niche. In the US, relaxing regulations and a fragmented market place represent a true opportunity to build elevated and trusted cannabinoid derivative consumer brands”. Mr. Useche continued: “In the industrial hemp derivatives space there is rapid proliferation of cannabinoids-based products like CBG and CBD. The challenge, however, is Branding, Quality and Customer Experience, all areas that RLV intends to leverage through its channel expertise.”
The Company’s strategic direction is very much in-line with its core business, which includes the creation of a portfolio of online, direct to consumer retail brands in Health and Wellness, both organically, through licensing agreements and via acquisitions.
The Company understands this is a fast-evolving regulatory environment. In order ensure the adoption of a full legal and compliant framework, the Company is assembling a team of legal and business experts from the space.
About the Market
According to a report from Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is expected to reach $63.5 billion in 2024, growing at a compound annual growth rate of 21.1 percent during the forecast years. North America accounts for over 49% of the market, with the U.S. being the single largest market.
A Major segment of the legal cannabis industry is the hemp-derived cannabidiol (CBD) market. According to a report by Forbes, Brightfield Group projects that Hemp-derived cannabidiol (CBD) will be a billion-dollar market in just three years. CBD products do not have any psychotropic effects and are usually used for medical purposes. Brightfield’s data estimates that hemp CBD sales have already hit $170 million in 2016 and at a 55% compound annual growth rate over the next five years the market will cross the billion-dollar mark. According to Statista, it is estimated that in the year 2020 CBD consumer sales will total around 1.15 billion U.S. dollars. Brightfield determined that 64.5% of the sales come through the online channel followed by 17.8% from physical points of sale.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Targets 83 Million Unique Monthly Visitors and 26 Countries Through European Expansion of Bioganix(R)
Momentum Public Relations
Press Release: April 5 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce that it has started the process of establishing European presence for the new Bioganix® brand in partnership with several online partners, including Amazon. Management will be doing an initial launch of eight best selling products, which will be live online on the week of the May 21, 2018 with full marketing launch by mid summer.
Highlights
- Bioganix® has started European expansion with online partners, including Amazon
- Initial launch of eight best selling products the week of May 21, 2018
Impact on the Business
- Presence in Europe adds 83M monthly unique visitors, over 200M new customers and access to 26 European Countries
- Increased competitive advantage and insulation from seasonality in sales
- Building the “trusted” Bioganix® brand equity internationally to a loyal consumer base
Impact on Shareholders
- Management is investing in growing its main retail asset internationally to deliver sustainable value to customers and shareholders alike
- Exposure of RLV to potential European equity investors through its Frankfurt listing
Aurelio Useche, CEO of Relevium, stated: “The decision to expand to Europe was driven by several key indicators including Amazon’s current investment in the region, access to 230M new customers buying online, higher basket sizes and lower competition. We believe the new Bioganix® brand is poised to gain customer acceptance as a “trusted” brand and successful consumer engagement in the European market”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
Relevium Technologies Inc.
+1.888.528.8687
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in Relevium Technologies
Relevium Announces All-Time Record High of Units Sales for Bioganix(R) in March
Momentum Public Relations
Press Release: April 3 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to report an all-time record high in unit sales for the month of March 2018.
The reported record high of 16,549 units, which was achieved in a seasonally low period, reflects increased online demand for the Bioganix® established product line, which is expected to translate into sales in excess of $439,000 for the month of March. The monthly high did not include the effect from new product launches, which are expected to have an incremental positive impact over the next six months.
The company’s all-time record high of units sold is an important achievement for Relevium’s Bioganix®brand. The Company continues to increase its subscriber base and number of SKUs, now totaling over 230,000 and 38 respectively.
Impact on the Business
- Increase of Bioganix® demand sets the stage for successful launch of new products
- The results indicate that the company’s investment in Mach 2.0 Marketing Engine is starting to pay dividends
Impact on Shareholders
- Increased confidence that management remains engaged on delivering sustainable value to its brands, customers and shareholders
- Incremental value to the acquired Bioganix® business through increased brand equity, exclusive product lines and geographic expansion
- Relevium is steadily building solid base for shareholder value creation, which will deliver future dividends
Abis Hussain, SMO of Relevium, stated: “The implications of this may seem trivial, but the results form this month in a seasonally low period indicate that Mach 2.0 is working as designed. We expect this to also have a positive impact on new products launches over the next six months.”
Aurelio Useche, CEO of Relevium, stated: “This is the first real test of the capabilities of our marketing engine following months of adjustments and beta testing. This small but important success is an important achievement for the company and for our digital marketing and operating teams.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Relevium Launches New Bioganix Brand Architecture
Momentum Public Relations
Press Release March 29 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce it has completed the re-positioning of its Bioganix brand. The new re-positioning enhances Bioganix around the key branding points of Credibility, Quality and Trust. The Company will be rolling out its new brand and new packaging immediately.
The Company is also launching its new website in the first week of April and all new product launches will adopt the guidelines of the new brand architecture that lays out a roadmap to our continued and future success.
Highlights
- Relevium launches new Bioganix brand
- The elevated brand will be catered around Credibility, Quality and Trust
- New Bioganix website launched first week of April
Impact on the Business
- Key differentiation in a very competitive market
- Elevated new brand with premium and exclusive products
- Increased brand equity and recognition
Impact on Shareholders
- Incremental value to the Bioganix assets
- Higher brand recognition = Increased public company awareness
- Steady building of shareholder value for future dividends
Aurelio Useche, CEO of Relevium, stated: “Our team has been working diligently over the last couple of months to launch the newly designed, more recognizable and elevated Bioganix brand,” Mr. Useche stated further: “We are positioning the brand as a recognizable and trusted source of goodness.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
- Published in Relevium Technologies
Relevium Provides H2 Guidance for Bioganix, Acquisitions and Legal Hemp Derivatives
Momentum Public Relations
Press Release: March 2 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to provide guidance on its strategy for its core e-commerce business for the second half of fiscal year ending June 30, 2018.
Highlights
- Bioganix® strategy and revenue expansion
- Official launch of Planet Hemp products
- Introduction and launch of Heart and Eye Health Omega 7 products
- Guidance on legal hemp derivatives for nutraceutical and skin care
- Launching of first pet care product
- European expansion of Bioganix brand
- Strategy and guidance for actionable M&A opportunities
Bioganix Strategy and Revenue Expansion
The Company has shifted its focus from daily operations optimization to increasing brand value. As such, Bioganix® is undergoing a major brand facelift which will better represent the values presentation and promise to our growing customer base. Words like Credibility, Quality, Trust, Elevated, Accessible, Centered, Confident, Wellness and Self-Actualization will be at the core of the new presentation to the market, with the objective at seeking higher conversion rates and brand loyalty within a more informed and wider audience base.
Relevium has been working with a newly extended supplier base and intends to launch sixteen (16) new products under the Bioganix® product brand before June 30, 2018. These new products will represent the first set of products launched entirely by the Relevium Operations Team since taking control of the business in July of 2017.
Official Launch of Planet Hemp Products
Since signing the exclusive product agreement with Hempco and PlanetHemp, the Company has been working closely with the team at Hempco to launch the PlanetHemp brand in Amazon US and UK. The team at Relevium will be launching five (5) PlanetHemp products in in H2 2018.
Abis Hussain, Senior Marketing Officer at Relevium stated: “We are seeing a huge appetite for hemp nutrition, skin care and hemp derived CBD products selling in legal jurisdictions online, both in the UK and US.” Mr. Hussain continued: “With increasing media exposure and regulatory changes, consumers are looking for hemp-based products to add them to their wellness programs. We feel that we are in the right position to capitalize on this segment.”
Introduction and launch of Heart and Eye Health Omega 7 products
Following the signing of the exclusivity agreement with Tersus for Provinol Ultra-Purified Omega 7products, the Company is in the process of building a premium brand and online assets for a new line of research-based vegan and fish oil based product line. The Omega 7 products for Heart and Vision will be the first of a series of products that will be launched and marketed as a premium product.
Mr. Hussain stated: “Omega products sell extremely well online. We are well positioned with exclusive and premium products like Ultra-Purified Omega 7, and our team is confident that a premium brand strategy will deliver optimal value to Relevium. The new premium brand will allow us to market products to a new demographic and market segment that is diversified from the Bioganix® core brand.”
Guidance on legal hemp derivatives for nutraceutical and skin care
Relevium has seen an increase in online content and traffic for hemp and hemp derivatives such as CBD. The market place is changing fast and the rate of adoption as well. In advance of fully launching products, brands and new business segments, the Company has begun accumulating a portfolio of domain names and is also building online assets for an elevated an trusted brand in the space.
The Company has been actively qualifying various suppliers, vendors, products and research partners in the space and believes that launching products within the legal hemp derivative market in H2 2018 is feasible.
Management is working with its legal counsel to ensure full compliance within a fast-evolving space. In order to ensure compliance for online retail, the company has engaged experts to build a private Blockchain with the objective of supporting and ensuring compliance in the entire supply chain.
Mr. Useche stated: “We have been actively monitoring and working in this market. We are cognisant that e-commerce for hemp and hemp derivatives for over-the-counter and prescription formulations will be an enormous market. We believe to have the initial based to ensure we position an elevated, trusted and compliant Relevium brand in this space.”
Execution of product launches in the hemp, hemp derivatives including CBD will be dependent on compliance with laws and regulations in each jurisdiction and each e-commerce platform where products are to be offered.
Launching of first pet care product
Relevium previously announced the creation of a segment of pet-focused products. The Company expects to launch its first products to include research-based joint and brain health formulations, both products currently trending online in 2018.
European expansion of Bioganix brand
The Company has been working on building out distribution for the European Union (“E.-U.”), notably in the United Kingdom, Germany, France, Spain and Italy. Initially focused on the geographical expansion of the BioGanix brand, Relevium will launch brands and products in the E.-U. as permitted by law.
Strategy and guidance for actionable M&A opportunities
The Company’s acquisition strategy is now focused on three main parameters: (1) strategic fit, (2) diversification and (3) accionability, the latter greatly dependent on market conditions, deal structure and our own valuation in the market. The main objective is ensure that we deliver a target that adds value to the portfolio and is well structured to limit the dilution effect.
The pipeline for acquisitions has been as high as USD 120,000,000 in cash flows to acquire. Depending on marketplace fluctuations, the pipeline is rarely lower than USD 50,000,000 in cash flow to acquire.
Mr. Useche stated: “The acquisition parameters from inception have been clear: we want to buy assets with high margins and pay low multiples, but there must be strategic fit and brand value add to our current business. We remain very active and in discussions but have yet to find the perfect candidate for our second acquisition that meets our more stringent selection process.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
Relevium Technologies Inc.
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies